Double maintains 4 strategies that include RARE - Ultragenyx Pharmaceutical, Inc.
Current Value
$34.681 Year Return
Current Value
$34.681 Year Return
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
SHYD | -0.19% | $318.05M | 0.35% |
BUXX | -0.48% | $284.43M | 0.25% |
KMLM | 0.60% | $188.32M | 0.9% |
STPZ | 0.67% | $446.46M | 0.2% |
JMST | -1.14% | $3.65B | 0.18% |
TDTT | 1.23% | $2.47B | 0.18% |
FXY | -1.37% | $838.61M | 0.4% |
LDUR | 1.60% | $849.09M | 0.5% |
KRBN | 1.65% | $160.09M | 0.85% |
WEAT | 1.66% | $115.83M | 0.28% |
BIL | -1.81% | $45.95B | 0.1356% |
TBLL | -1.84% | $2.46B | 0.08% |
UGA | 1.91% | $73.47M | 0.97% |
UNG | 2.00% | $371.83M | 1.06% |
SMB | 2.13% | $269.10M | 0.07% |
XHLF | -2.19% | $1.46B | 0.03% |
DBE | 2.24% | $48.48M | 0.77% |
FMF | 2.38% | $153.73M | 0.95% |
CANE | -2.77% | $10.71M | 0.29% |
USL | 2.99% | $41.76M | 0.85% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
TAIL | -28.83% | $140.49M | 0.59% |
BTAL | -28.49% | $361.41M | 1.43% |
VIXY | -26.97% | $109.64M | 0.85% |
TPMN | -18.26% | $31.54M | 0.65% |
CTA | -12.14% | $1.05B | 0.76% |
USFR | -10.93% | $18.91B | 0.15% |
USDU | -10.23% | $173.44M | 0.5% |
UUP | -10.02% | $292.27M | 0.77% |
CLIP | -8.08% | $1.50B | 0.07% |
BILZ | -8.03% | $876.85M | 0.14% |
IVOL | -7.89% | $353.94M | 1.02% |
TFLO | -7.49% | $7.06B | 0.15% |
KCCA | -6.78% | $97.18M | 0.87% |
FTSD | -5.19% | $212.46M | 0.25% |
SHYM | -5.03% | $322.93M | 0.35% |
ULST | -3.53% | $637.77M | 0.2% |
CANE | -2.77% | $10.71M | 0.29% |
XHLF | -2.19% | $1.46B | 0.03% |
TBLL | -1.84% | $2.46B | 0.08% |
BIL | -1.81% | $45.95B | 0.1356% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CRNX | 51.60% | $2.92B | -39.88% | 0.00% |
COGT | 50.33% | $543.09M | -36.14% | 0.00% |
RVMD | 50.17% | $7.35B | +1.15% | 0.00% |
DNLI | 48.48% | $2.06B | -30.04% | 0.00% |
SNDX | 47.10% | $770.13M | -57.22% | 0.00% |
DASH | 46.67% | $83.52B | +69.68% | 0.00% |
ARWR | 46.64% | $2.12B | -38.64% | 0.00% |
RNA | 46.63% | $3.49B | +0.87% | 0.00% |
NTLA | 46.56% | $836.43M | -69.14% | 0.00% |
IONS | 45.48% | $5.25B | -12.31% | 0.00% |
RCKT | 45.47% | $724.54M | -71.26% | 0.00% |
KYMR | 44.83% | $1.95B | -15.67% | 0.00% |
KRYS | 44.79% | $3.77B | -20.42% | 0.00% |
BEAM | 44.74% | $1.73B | -27.49% | 0.00% |
XNCR | 44.60% | $583.60M | -63.49% | 0.00% |
NUVL | 44.56% | $5.10B | -2.26% | 0.00% |
CERS | 44.55% | $246.60M | -34.18% | 0.00% |
IDYA | 44.32% | $1.52B | -58.32% | 0.00% |
ROIV | 44.24% | $7.68B | -5.70% | 0.00% |
ACLX | 43.41% | $3.22B | +10.72% | 0.00% |
Yahoo
NOVATO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) released its 2024 Impact Report today, which covers the company’s approach to corporate responsibility. The report highlights efforts to transform the lives of individuals and families affected by rare diseases, empower its employees, and make a meaningful impact on the communities it operates within and serves. “Since founding Ultragenyx 15 years ago, I’ve sought to build a next-generation rare diseas
Yahoo
Ultragenyx Pharmaceutical Inc. ( NASDAQ:RARE ) shareholders are probably feeling a little disappointed, since its...
Yahoo
Truist lowered the firm’s price target on Ultragenyx (RARE) to $100 from $140 and keeps a Buy rating on the shares. The company’s Q1 results were in-line and the management reiterated its FY25 revenue guidance, though the firm’s price target is cut on tampered outlook for gene therapy programs, the analyst tells investors in a research note. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read
Yahoo
Ultragenyx Pharmaceutical ( NASDAQ:RARE ) First Quarter 2025 Results Key Financial Results Revenue: US$139.3m (up 28...
Yahoo
NOVATO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Howard Horn, the company's chief financial officer and executive vice president, will participate in a fireside at Bank of America’s 2025 Healthcare Conference on Tuesday, May 13, 2025, at 8:00 a.m. PT. The live and archived webcast of t
Yahoo
Q1 2025 Ultragenyx Pharmaceutical Inc Earnings Call
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XBI | 63.34% | $4.85B | 0.35% |
GNOM | 62.66% | $40.65M | 0.5% |
IBB | 58.38% | $5.22B | 0.45% |
BBH | 54.07% | $327.42M | 0.35% |
PTH | 53.62% | $96.56M | 0.6% |
PINK | 53.26% | $131.52M | 0.5% |
PBE | 52.85% | $214.12M | 0.58% |
FBT | 52.61% | $994.71M | 0.56% |
ARKG | 50.96% | $944.78M | 0.75% |
XPH | 48.55% | $136.58M | 0.35% |
VHT | 48.25% | $14.92B | 0.09% |
FHLC | 48.16% | $2.42B | 0.084% |
FXH | 47.03% | $891.82M | 0.62% |
KJUL | 46.05% | $113.35M | 0.79% |
IYH | 45.81% | $2.78B | 0.39% |
IXJ | 45.26% | $3.78B | 0.41% |
QQQJ | 45.05% | $610.08M | 0.15% |
IWO | 44.44% | $11.36B | 0.24% |
XLV | 43.91% | $34.49B | 0.09% |
AOM | 43.91% | $1.50B | 0.15% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
FMTO | -10.34% | $45.74M | -99.96% | 0.00% |
HEES | -10.09% | $3.52B | +99.54% | 1.15% |
LITB | -8.63% | $21.28M | -72.45% | 0.00% |
BTCT | -7.27% | $25.35M | +93.08% | 0.00% |
AIFU | -7.19% | $9.85M | -95.03% | 0.00% |
KR | -6.69% | $44.68B | +24.17% | 1.89% |
NEUE | -5.97% | $62.05M | +13.56% | 0.00% |
AQB | -5.89% | $2.96M | -61.58% | 0.00% |
VHC | -5.27% | $34.69M | +74.89% | 0.00% |
PPC | -5.17% | $11.21B | +41.54% | 0.00% |
EXC | -4.78% | $43.84B | +12.45% | 3.59% |
VSA | -4.66% | $7.04M | -49.24% | 0.00% |
PRA | -4.37% | $1.19B | +58.17% | 0.00% |
COR | -3.82% | $55.43B | +28.90% | 0.56% |
T | -3.55% | $196.66B | +57.98% | 4.07% |
VZ | -3.30% | $183.32B | +8.02% | 6.21% |
GO | -2.77% | $1.37B | -35.98% | 0.00% |
FARO | -2.46% | $812.11M | +115.84% | 0.00% |
OCFT | -2.41% | $265.28M | +232.26% | 0.00% |
CODI | -2.18% | $580.07M | -65.16% | 12.97% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
AWK | -0.03% | $27.37B | +4.54% | 2.22% |
SEG | 0.16% | $239.93M | -26.61% | 0.00% |
CNR | -0.18% | $3.82B | -17.62% | 0.83% |
LTM | -0.19% | $11.01B | -96.75% | 2.75% |
TME | -0.21% | $11.45B | +5.62% | 1.90% |
DADA | -0.37% | $526.11M | +11.54% | 0.00% |
CARV | 0.39% | $7.41M | -22.87% | 0.00% |
EDU | 0.47% | $7.99B | -41.11% | 0.00% |
CMTL | 0.48% | $50.48M | -14.43% | 0.00% |
SRDX | 0.56% | $400.81M | -17.75% | 0.00% |
CNP | 0.56% | $24.30B | +24.35% | 2.82% |
MO | -0.57% | $97.80B | +26.35% | 6.94% |
SRRK | 0.79% | $2.92B | +115.29% | 0.00% |
PLYA | 0.81% | $1.65B | +57.38% | 0.00% |
BPT | 0.84% | $13.70M | -73.66% | 0.00% |
PINC | 0.95% | $1.88B | +15.22% | 3.69% |
CHD | -0.99% | $23.29B | -11.36% | 1.23% |
FYBR | 1.01% | $9.16B | +36.87% | 0.00% |
HSY | 1.02% | $33.16B | -21.37% | 3.44% |
CME | 1.13% | $98.74B | +28.80% | 3.84% |